MedTrace Logo

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

NCT00591253 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 413

Last updated 2011-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.

Conditions

Interventions

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.

DRUG

Placebo

Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.

Sponsors & Collaborators

Principal Investigators

  • Executive Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591253 on ClinicalTrials.gov